A Review of the Antimicrobial Activity of the Fluoroquinolones

References

• Lesher GY, Froelich EJ, Gruett MD, et al. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 5: 1063–1065.
   Google Scholar
• Ronald AR, Turck M, Petersdorf RG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med, 1966; 275: 1081–1089.
   Google Scholar
• Smith JT. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceut J 1984; 233: 299–305.
   Google Scholar
• Turner FJ, Ringel SM, Martin JF, et al.: Oxolinic acid, a new synthetic antimicrobial agent. 1. In vitro and in vivo activity. Antimicrob Agents Chemother, 1967; 1968: 475–478.
   Google Scholar
• Wick WE, Preston DA, White WA, Gordee RS. Compound 64716, a new synthetic antibacterial agent. Antimicrob Agents Chemother, 1973; 4: 415–420.
   Google Scholar
• Cameron DW, Ronald AR. The older DNA — gyrase inhibitors. Res Clin For 1985; 7: 81–87.
   Google Scholar
• Shimizu M, Takase Y, Nakamura S, et al. Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa. In vitro properties. Antimicrob Agents Chemother, 1975; 8: 132–138.
   Google Scholar
• Rohlfing SR, Gerster JF, Kvam DC. Bioevaluation of the antibacterial flumequine for urinary tract use. Antimicrob Agents Chemother, 1976; 10: 20–24.
   Google Scholar
• Ito A, Hirai K, Inoue M, et al. In vitro antibacterial activity of AM — 715, a new nalidixic acid analog. Antimicrob. Agents Chemother, 1980; 17: 103–108.
   Google Scholar
• Felmingham D, O’Hare MD, Robbins MJ, et al. Comparative in vitro studies with 4 — quinolone antimicrobials. Drugs Exptl Clin Res, 1985; XI: 317–329.
   Google Scholar
• Barry AL, Jones RN, Thornsberry C, et al. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother, 1984; 25: 633–637.
   Google Scholar
• Neu HC, Chin N. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother, 1989; 33: 1105–1107.
   Google Scholar
• Chu DTW, Fernandes PB. Structure activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 1989; 33: 131–135.
   Google Scholar
• Phillips I, King A. Comparative activity of the 4 — quinolones. Rev Infect Dis, 1988; 10(Suppl. 1): 70–76.
   Google Scholar
• Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother, 1985; 28: 581–586.
   Google Scholar
• Janknegt R. Fluorinated quinolones: a review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. Pharmaceutisch Weekblad Scientific Edition, 1986; 8: 1–21.
   Google Scholar
• King A, Phillips I. The comparative in vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother, 1986; 18 (Suppl. D): 1–20.
   Google Scholar
• Gruneberg RN, Felmingham D, O’Hare MD, Robbins MJ: The comparative in vitro activity of ofloxacin. J. Antimicrob Chemother, 1988; 22 (Suppl. C): 9–19.
   Google Scholar
• Auckenthaler R, Michea-Hamzehpour M, Pechere JC. In vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother, 1986; 17 (Suppl. B): 29–39.
   Google Scholar
• Paton JH, Reeves DS: Fluoroquinolone antibiotics: microbiology, pharmacokinetics and clinical use. Drugs, 1988; 36: 193–228.
   Google Scholar
• Asahara M, Tsuji A, Goto S, et al. In vitro and in vivo activities of QA — 241, a new tricyclic quinolone derivative. Antimicrob Agents Chemother, 1989; 33: 1144–1152.
   Google Scholar
• Goldstein EJC, Citron DM, Vagvolgyi AE, Gombert ME. Susceptibility of Eikenella corrodens to newer and older quinolones. Antimicrob Agents Chemother, 1986; 30: 172–173.
   Google Scholar
• Nakamura S, Minami A, Nakata K, Kurobe N. In vitro and in vivo antibacterial activities of AT — 4140, a new broad- spectrum quinolone. Antimicrob Agents Chemother, 1989; 33: 1167–1173.
   Google Scholar
• Yousuf-Kahn M, Dizon M, Kiel FW: Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother, 1989; 33: 1409–1410.
   Google Scholar
• Van der Auwera P, Scorneaux B. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of β-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother., 1985; 28: 37–40.
   Google Scholar
• Simor AE, Ferro S, Low DE: Comparative in vitro activities of six new fluoroquinolones and other oral available antimicrobial agents against Campylobacter pylori. Antimicrob Agents Chemother, 1989; 33: 108–109.
   Google Scholar
• Saito A, Koga H, Shigeno H, et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother, 1986; 18: 251–260.
   Google Scholar
• Liebowitz LD, Saunders J, Fehler G, Ballard RC. In vitro activity of A — 56619 (Difloxacin), A- 56620, and other new quinolone antimicrobial agents against genital pathogens. Antimicrob Agents Chemother, 1986; 30: 948–950.
   Google Scholar
• Cornaglia G, Pompei R, Dainelli B, Satta G. In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital. Antimicrob. Agents Chemother. 1987; 31: 1651–1655.
   Google Scholar
• Barry AL, Jones RN. In vitro activities of temafloxacin, tosufloxacin (A — 61827) and five other fluoroquinolone agents. J Antimicrob Chemother, 1989; 23: 527–535.
   Google Scholar
• Fernandez-Roblas R, Prieto S, Santamaria M, et al. Activity of nine antimicrobial agents against Corynebacterium group D2 strains isolated from clinical specimens and skin. Antimicrob Agents Chemother, 1987; 31: 821–822.
   Google Scholar
• Mazzulli T, Simor AE, Jaeger R, et al. Comparative in vitro activities of several new fluoroquinolones and β — lactam agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother, 1990; 34: 467–469.
   Google Scholar
• Brumfitt W, Franklin I, Grady D, et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7 — day course to human volunteers. Antimicrob Agents Chemother, 1984; 26: 757–761.
   Google Scholar
• Alcock SR, Ledingham I McA. Selective decontamination of the digestive tract and prevention of infection in intensive care units. J Antimicrob Chemother, 1988; 22: 97–101.
   Google Scholar
• Giuliano M, Pantosti A, Gentile G, et al. Effects on intestinal and oral microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients. Antimicrob. Agents Chemother, 1989; 33: 1709–1713.
   Google Scholar
• Gorzynski EA, Gutman SI, Allen W: Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother, 1989; 33: 591–592.
   Google Scholar
• Leysen DC, Heamers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother, 1989; 33: 1–5.
   Google Scholar
• Davies S, Sparham PD, Spencer RC. Comparative in vitro activity of five fluoroquinolones against Mycobacteria. J Antimicrob Chemother, 1987; 19: 605–609.
   Google Scholar
• Wallace Jr, RA, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single- drug therapy. Antimicrob Agents Chemother, 1990; 34: 65–70.
   Google Scholar
• Franzblau SG, White KE. Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. Antimicrob Agents Chemother, 1990; 34: 229–231.
   Google Scholar
• Aznar J, Caballero MC, Lozano MC, Miguel C. Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother, 1985; 27: 76–78.
   Google Scholar
• Kenny GE, Hooton TM, Roberts MC, et al. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob Agents Chemother, 1989; 33: 103–107.
   Google Scholar
• Nagayama A, Nakao T, Taen H: In vitro activities of ofloxacin and four other new quinoline- carboxylic acids against Chlamydia trachomatis. Antimicrob Agents Chemother, 1988; 32: 1735–1737.
   Google Scholar
• Perea EJ. Treatment of genital chlamydial infections with ciprofloxacin or ofloxacin. Quinolones Bull 1989; 5: 1–3.
   Google Scholar
• Raoult D, Roussellier P, Gaucher V, et al. In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay. Antimicrob Agents Chemother, 1986; 29: 424–425.
   Google Scholar
• Raoult D, Yeaman R, Baca OG. Susceptibility of Coxiella burnetii to pefloxacin and ofloxacin in ovo, and in persistently infected L929 cells. Antimicrob Agents Chemother, 1989; 33: 621–623.
   Google Scholar
• Yeaman MR, Mitscher LA, Baca OG. In vitro susceptibility of Coxiella burnetii to antibiotics including several quinolones. Antimicrob Agents Chemother, 1987; 31: 1079–1084.
   Google Scholar
• Fass RJ. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother, 1983; 24: 568–574.
   Google Scholar
• Chin N, Neu HC: Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother, 1984; 25: 319–326.
   Google Scholar
• Kayser FH, Novak J: In vitro activity of ciprofloxacin against Gram — positive bacteria. Am J Med, 1987; 82 (Suppl. A): 33–39.
   Google Scholar
• Hohl PH, Felber AM. Effect of method, medium, pH and inoculum on the in vitro antibacterial activities of fleroxacin and norfloxacin. J Antimicrob Chemother, 1988; 22 (Suppl D): 71–80.
   Google Scholar
• Blaser J, Dudley MN, Gilbert D, Zinner SH: Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother. 1986; 29: 927–929.
   Google Scholar
• Eliopoulos GM, Gardella A, Moellering RC. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother, 1984; 25: 331–335.
   Google Scholar
• Smith SM, Eng RHK, Berman E. The effect of ciprofloxacin on methicillin- resistant Staphylococcus aureus. J Antimicrob Chemother, 1986; 17: 287–295.
   Google Scholar
• Gesu GP, Eftimiadi C, Debbia E, Schito GC. Effects of changes in pH, medium and inoculum size on the in vitro activity of different quinolone and fluoroquinolone antibiotics against urinary pathogens. Drugs Exptl Clin Res, 1987; XIII: 79–84.
   Google Scholar
• Reeves DS, Bywater MJ, Holt HA, White LO. In vitro studies with ciprofloxacin, a new 4 — quinolone compound. J Antimicrob Chemother, 1984; 13: 333–346.
   Google Scholar
• Smith JT, Ratcliffe NT. Activity of the 4 — quinolone antibacterials at physiological pH values. In: J. Ishigami ed., Proceedings of the 14th International Congress of Chemotherapy Kyoto, 1985: 1861–1862.
   Google Scholar
• Nakamura S, Minami A, Katae H, et al. In vitro antibacterial properties of AT — 2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother, 1983; 23: 641–648.
   Google Scholar
• Zeiler HJ. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin. Drugs Exptl Clin Res, 1985; XL 335–338.
   Google Scholar
• Chin N, Neu HC. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new β - lactams, aminoglycosides and trimethoprim. Antimicrob Agents Chemother, 1983; 24: 754–763.
   Google Scholar
• Smith JT, Ratcliffe NT. Effect of pH and magnesium on the in vitro activity of ciprofloxacin. In: H.C. Neu, H. Weuta, eds. 1st International Ciprofloxacin Workshop Proceedings, Amsterdam, Elsevier Science (Excerpta Medica), 1986: 12–16.
   Google Scholar
• Neu HC. The effects of cations upon the activity of quinolone agents. Quinolones Bull 1985: April, 1.
   Google Scholar
• Hirschhorn L, Neu HC. Factors influencing the in vitro activity of two new aryl — fluoroquinolone antimicrobial agents, difloxacin (A- 56619) and A- 56620. Antimicrob Agents Chemother, 1986; 30: 143–146.
   Google Scholar
• Black QAH, Israel KS, Wolen RL, Brier GL et al. Pharmacology of cinoxacin in humans. Antimicrob Agents Chemother, 1979; 15: 165–170.
   Google Scholar
• Gordon RC, Stevens LI, Edmiston CE, Jr, Mohan K. Comparative in vitro studies of cinoxacin, nalidixic acid and oxolinic acid. Antimicrob Agents Chemother. 1976; 10: 918–920.
   Google Scholar
• Hooper DC, Wolfson JS: Mode of action of the quinolone antimicrobial agents. Rev Infect Dis, 1988; 10 (Suppl. 1): 14–19.
   Google Scholar
• Ratcliffe NT, Smith JT. Ciprofloxacin and ofloxacin exhibit a rifampicin- resistant bactericidal mechanism not detectable in other 4- quinolone antibacterial agents. J Pharm Pharmacol 1984; 36: 59P.
   Google Scholar
• Zeiler HJ. The in vitro activity and in vivo activity of ciprofloxacin. Eur J Clin Microbiol, 1984; 3: 339–343.
   Google Scholar
• Ratcliffe NT, Smith JT. Norfloxacin has a novel bactericidal mechanism unrelated to that of other 4- quinolones. J Pharm Pharmacol 1985; 37: 92P.
   Google Scholar
• Lewin CS, Smith JT. Bactericidal mechanisms of ofloxacin. J Antimicrob Chemother, 1988; 22 (Suppl. C): 1–8.
   Google Scholar
• Lewin CS, Smith JT. Bactericidal activity of ciprofloxacin against Staphylococcus aureus. J Antimicrob Chemother, 1989; 24: 84–85.
   Google Scholar
• Smith JT. The mode of action of 4- quinolones and possible mechanisms of resistance. J Antimicrob Chemother, 1986; 18 (Suppl. D), 21–29.
   Google Scholar
• Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother, 1975; 8: 251–261.
   Google Scholar
• Lewin CS, Allen RA, Amyes SGB: Potential mechanisms of resistance to the modern fluorinated 4- quinolones. J Med Microbiol, 1990; 31: 153–162.
   Google Scholar
• Panhotra BR, Desai B, Sharma PL. Nalidixic- acid resistant Shigella dysenteriae I. Lancet, 1985; 1: 763.
   Google Scholar
• Munshi MH, Sack DA, Haider K, Ahmed ZV. Plasmid- mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet, 1987; 2: 419–421.
   Google Scholar
• Cullmann W, Stieglitz M, Baars B, Opferkuch W. Comparative evaluation of recently developed quinolone compounds- with a note on the frequency of resistant mutants. Chemotherapy, 1985; 31: 19–28.
   Google Scholar
• Piddock LJV, Wise R. Mechanisms of resistance to quinolones and clinical perspectives. J Antimicrob Chemother, 1989; 23: 475–480.
   Google Scholar
• Robillard NJ, Scarpa AL. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother, 1988; 32: 535–539.
   Google Scholar
• Smith JT. Mutational resistance to 4- quinolone antibacterial agents. Eur J Clin Microbiol, 1984; 3: 347–350.
   Google Scholar
• Limb DI, Dabbs DJW, Spencer RC. In vitro selection of bacteria resistant to the 4- quinolone agents. J Antimicrob Chemother, 1987; 19: 65–71.
   Google Scholar
• Hirai K, Aoyama H, Suzue S, et al. Isolation and characterization of norfloxacin- resistant mutants of Escherichia coli K12. Antimicrob Agents Chemother, 1986; 30: 248–253.
   Google Scholar
• Kresken M, Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother, 1988; 32: 1285–1288.
   Google Scholar
• Desgrandchamps D, Munzinger J. Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens. Antimicrob Agents Chemother, 1989; 33: 595–596.
   Google Scholar
• Daschner FD, Just HM: In vitro activity of five quinoline derivatives against nosocomial isolates of Staphylococcus and Pseudomonas species. Eur J Clin Microbiol, 1985; 4: 72–73.
   Google Scholar
• Fass RJ, Helsel VL. In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphy-lococcal drugs. Antimicrob Agents Chemother, 1987; 31: 1457–1460.
   Google Scholar
• Smith SM. In vitro comparison of A- 56619, A56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin and ofloxacin against methicillin- resistant Staphylococcus aureus. Antimicrob Agents Chemother, 1986; 29: 325–326.
   Google Scholar
• Lauwers S, Vincken W, Naessens A, Pierard D. Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units. J Antimicrob Chemother, 1986; 17 (Suppl. B): 111–115.
   Google Scholar
• Gorkiewicz-Petkow A, Weuta H, Jablonska S, et al. Bacterial infections of the skin treated with ciprofloxacin. Infection 1988; 16 (Suppl. 1): 55–56.
   Google Scholar
• Mulligan ME, Ruane PJ, Johnston L, et al. Ciprofloxacin for eradication of methicillin- resistant Staphylococcus aureus colonization. Am J Med, 1987; 82 (4A): 215–219.
   Google Scholar
• Isaacs RD, Kunke PJ, Cohen RL, Smith JW. Ciprofloxacin resistance in epidemic methicillin-resistant Staphylococcus aureus. Lancet 1988; ii: 843.
   Google Scholar
• Schaefler S. Methicillin- resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol, 1989; 27: 335–336.
   Google Scholar
• Smith GM, Cashmore C, Leyland MJ. Ciprofloxacin resistant staphylococci. Lancet 1985; ii: 949.
   Google Scholar
• Oppenheim BA, Hartley JW, Lee W, Burnie JP: Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. Br Med J, 1989; 299: 294–297.
   Google Scholar
• Shalit I, Berger SA, Gorea A, Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother, 1989; 33: 593–594.
   Google Scholar
• Jean-Pierre H, Boyer G, Jean A, Darbas H. Evolution de la resistance des Staphylococcus aureus a la pefloxacine. Etude portant sur 782 souches isolees en 1985 et 1986. Path Biol, 1988; 36: 956–958.
   Google Scholar
• Maple PAC, Hamilton-Miller JMT, Brumfitt W. Ciprofloxacin resistance in methicillin- and gentamicin- resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis, 1989; 8: 622–624.
   Google Scholar
• Kaatz GW, Seo SM: Mechanisms of ciprofloxacin resistance in Staphylococcus aureus. Abstracts of the Annual Meeting of the American Society for Microbiology 1989, A-98.
   Google Scholar
• Ubukata K, Itoh-Yamashita N, Konno M. Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 1989; 33: 1533–1539.
   Google Scholar
• Maple PAC, Hamilton-Miller JMT, Brumfitt W. World-wide antibiotic resistance in methicillin- resistant Staphylococcus aureus. Lancet, 1989; 1: 537–540.
   Google Scholar
• Phillips I, King A, Shannon K. In vitro properties of the quinolones. In: VT Andriole ed., The Quinolones London: Academic Press, 1988: 83–117.
   Google Scholar
• Hardy DJ, Swanson RN, Hensey DM, Ramer NR et al. Comparative antibacterial activities of temafloxacin hydrochloride (A- 62254) and two reference fluoroquinolones. Antimicrob Agents Chemother, 1987; 31: 1768–1774.
   Google Scholar
• Chin N-X, Brittain DC, Neu HC. In vitro activity of Ro 23-6240, a new fluorinated 4- quinolone. Antimicrob Agents Chemother, 1986; 29: 675–680.
   Google Scholar
• Stamm JM, Hanson CW, Chu DTW, et al. In vitro evaluation of A- 56619 (difloxacin) and A- 56620: new arylfluoroquinolones. Antimicrob. Agents Chemother, 1986; 29: 193–200.
   Google Scholar
• Van der Auwera P, Grenier P, Pierard DJ. In vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin. Antimicrob Chemother, 1989; 23: 209–219.
   Google Scholar
• Venezia RA, Prymas LA, Shayegani A, et al. In vitro activities of amifloxacin and two of its metabolites. Antimicrob Agents Chemother, 1989; 33: 762–766.
   Google Scholar
• Fung-Tome J, Desiderio JV, Tsai YH, et al. In vitro and in vivo antibacterial properties of BMY 40062, a new fluoronaphthyridone. Antimicrob Agents Chemother, 1989; 33: 906–914.
   Google Scholar
• Rolston KVI, LeBlanc B, Gooch G, et al. In vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients. J Antimicrob Chemother, 1989; 23: 363–371.
   Google Scholar
• Eliopoulos GM, Klimm K, Rice LB, et al. Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob. Agents Chemother, 1990; 34: 1154–1159.
   Google Scholar
• Bryskier A, Labro MT. Quinolones and malaria: an avenue for the future. Quinolones Bull 1990; 6: 1–4.
   Google Scholar
• Kojima T, Inoue M, Mitsuhashi S. In vitro activity of AT- 4140 against quinolone- and methicillin- resistant Staphylococcus aureus. Antimicrob Agents Chemother, 1990; 34: 1123–1127.
   Google Scholar
• Sirot J, Chanal C, Petit A, Labia R. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated β-lactamases markedly active against third- generation cephalosporins: epidemiologic studies. Rev Infect Dis, 1988; 10: 850–859.
   Google Scholar